metricas
covid
Buscar en
Endocrinología, Diabetes y Nutrición
Toda la web
Inicio Endocrinología, Diabetes y Nutrición Influence of obesity and overweight in surgical outcomes of adrenalectomy for pr...
Journal Information
Vol. 70. Issue 9.
Pages 564-571 (November 2023)
Share
Share
Download PDF
More article options
Visits
446
Vol. 70. Issue 9.
Pages 564-571 (November 2023)
Original article
Full text access
Influence of obesity and overweight in surgical outcomes of adrenalectomy for primary adrenal disease: A cohort study of 146 cases
Influencia de la obesidad y el sobrepeso en los resultados quirúrgicos de la suprarrenalectomía por enfermedad suprarrenal primaria. Estudio de una cohorte de 146 casos
Visits
446
César Mínguez Ojedaa, Victoria Gómez Dos Santosa, Javier Álvaro Lorcaa, Ignacio Ruz-Caracuelb, Héctor Pianb, Alfonso Sanjuanbenito Dehesac, Francisco Javier Burgos Revillaa, Marta Araujo-Castrod,e,
Corresponding author
marta.araujo@salud.madrid.org

Corresponding author.
a Urology Department, Hospital Universitario Ramón y Cajal, IRYCIS, Madrid, Spain
b Pathology Department, Hospital Universitario Ramón y Cajal, IRYCIS, Madrid, Spain
c General Surgery Department, Hospital Universitario Ramón y Cajal, IRYCIS, Madrid, Spain
d Endocrinology & Nutrition Department, Hospital Universitario Ramón y Cajal, IRYCIS, Madrid, Spain
e Medicine Department, University of Alcalá, Madrid, Spain
This item has received
Article information
Abstract
Full Text
Bibliography
Download PDF
Statistics
Figures (2)
Tables (3)
Table 1. Baseline characteristics of the cohort study (n=146).
Table 2. Differences in presurgical, surgical and postsurgical variables between patients with and without obesity/overweight.
Table 3. Risk factors for postsurgical complications.
Show moreShow less
Abstract
Objective

To evaluate the impact of obesity and overweight on surgical outcomes in a large cohort of patients who underwent adrenalectomy due to benign or malignant primary adrenal disease.

Methods

A retrospective single-center study of patients without history of active extraadrenal malignancy, with adrenal tumors operated on consecutively in our center between January 2010 and December 2022. Obesity was defined as a body mass index (BMI)30kg/m2 and overweight as BMI between 25.0 and 30.0kg/m2.

Results

Of 146 patients with adrenal tumors who underwent adrenalectomy, 9.6% (n=14) were obese, 54.8% (n=80) overweight and 35.6% (n=52) normal weight. Obese patients had higher diastolic blood pressure (87.6±12.22 vs. 79.3±10.23mmHg, P=0.010) and a higher prevalence of dyslipidemia (57.1% vs. 25.8%, P=0.014) and bilateral tumors (14.3% vs. 3.1%, P=0.044) than non-obese patients. The rates of intraoperative and of postsurgical complications were similar between obese/overweight patients and patients with normal weight. However, a significantly higher rate of postsurgical complications (27.3% vs. 5.7%, P=0.009) and a longer hospital stay (5.4±1.39 vs. 3.5±1.78 days, P=0.007) were observed in patients with obesity than in non-obese patients. In the multivariant analysis, obesity, age, ASA>2 and tumor size were independent risk factors for postoperative complications, with obesity being the most important factor (OR 23.34 [2.23–244.24]).

Conclusion

Obesity and overweight are common conditions in patients who undergo adrenalectomy. Adrenalectomy is considered a safe procedure in patients with overweight, but it is associated with a higher risk of postsurgical complications and longer hospital stay in obese patients.

Keywords:
Obesity
Overweight
Adrenalectomy
Adrenal tumor
Resumen
Objetivo

Evaluar el impacto de la obesidad y el sobrepeso en los resultados quirúrgicos en una cohorte de pacientes que se sometieron a adrenalectomía debido a enfermedad suprarrenal primaria benigna o maligna.

Métodos

Estudio unicéntrico retrospectivo de pacientes sin antecedentes de neoplasia maligna extraadrenal activa con tumores suprarrenales operados de forma consecutiva en nuestro centro durante enero de 2010 y diciembre de 2022. Se definió obesidad como un índice de masa corporal (IMC) 30kg/m2 y sobrepeso como un IMC entre 25,0 y 30,0kg/m2.

Resultados

De 146 pacientes con tumores suprarrenales a los que se les realizó adrenalectomía, el 9,6% (n=14) presentaba obesidad, el 54,8% (n=80) sobrepeso y el 35,6% (n=52) normopeso. Los pacientes obesos tenían cifras más altas de tensión arterial diastólica (87,6±12,22 vs. 79,3±10,23mmHg; p=0,010) y una mayor prevalencia de dislipemia (57,1 vs. 25,8%; p=0,014) y de tumores bilaterales (14,3 vs. 3,1%; p=0,044) que los pacientes no obesos. La tasa de complicaciones intraoperatorias y posquirúrgicas fue similar entre pacientes obesos/con sobrepeso y pacientes con normopeso. Sin embargo, se observó una tasa significativamente mayor de complicaciones posquirúrgicas (27,3 vs. 5,7%; p=0,009) y una estancia hospitalaria más prolongada (5,4±1,39 vs. 3,5±1,78 días; p=0,007) en pacientes con obesidad que en los no obesos. En el análisis multivariante, la obesidad, la edad, un ASA>2 y el tamaño tumoral fueron factores de riesgo independientes de complicaciones postoperatorias, siendo la obesidad el factor más importante (OR: 23,34 [2,23-244,24]).

Conclusión

La obesidad y el sobrepeso son condiciones frecuentes en los pacientes que se someten a adrenalectomía. La suprarrenalectomía se considera un procedimiento seguro en los pacientes con sobrepeso, pero se asocia con un mayor riesgo de complicaciones posquirúrgicas y a una mayor estancia hospitalaria en los pacientes obesos.

Palabras clave:
Obesidad
Sobrepeso
Suprarrenalectomía
Tumor suprarrenal
Full Text
Introduction

Obesity is an increasingly common disease worldwide.1 Patients with obesity are usually at higher risk of intraoperative and postoperative complications due to the greater difficulty of anesthetic management, higher rate of conversion to open surgery, and higher number of surgical wound infections among others.2

Adrenalectomy can be performed by different approaches (open, laparoscopic, or robot-assisted). Today, laparoscopic adrenalectomy is considered the first-line treatment for most adrenal tumors.3 It has been demonstrated that laparoscopy compared with open adrenalectomy has a lower risk of intraoperative morbidity, shorter hospital stays, and fewer postoperative complications.3,4 Nevertheless, open adrenalectomy is still the technique of choice in patients with large tumors or with signs of infiltration of adjacent tissues.4 The rise in the number of obese patients in recent years, has increased the difficulty of the surgical technique, with a higher rate of conversion to open surgery in laparoscopic adrenalectomy (1–22%).5 Some other studies have examined the results of laparoscopic adrenalectomy in obese and non-obese patients.6 However, most of these studies are retrospective, the number of patients included is usually low, and they do not distinguish whether the indication of surgery was for a primary tumor or for metastasis, taking into account that patients with a previous oncological history tend to have a lower weight than patients with a primary adrenal tumor. To overcome these limitations, we have included all consecutive patients with adrenal tumors operated on in our center, but we have excluded those patients with metastatic tumors in the adrenal gland.

The aim of our study is to evaluate the impact of obesity on surgical outcomes in adrenal gland surgery in a large cohort of patients who underwent adrenalectomy due to benign or malignant primary adrenal disease.

Material and methodsStudy population

We designed a retrospective study performed at Ramón y Cajal University Hospital, Madrid, Spain, between January 1, 2010, and July 20, 2022. This study received approval from the Ethics Committee of our hospital (approval date: July 2020, Minutes 395). All patients diagnosed with an adrenal tumor who underwent adrenalectomy were included in the study. However, those with a history of active extra-adrenal malignancy and metastasis to the adrenal gland were excluded. In addition, two patients for whom information on anthropometric parameters was not available were excluded.

Data were extracted from the electronic medical records system and were collected in an electronic database (RedCAP® database). Information recorded in the database included demographic, clinical, biochemical, hormonal, radiological data, anesthetic risk [American Society of Anesthesiologists classification (ASA)], and variables related to preoperative, intraoperative, and surgical management.

Medical history of comorbidities at diagnosis including hypertension, type 2 diabetes mellitus, obesity, dyslipidemia, cerebrovascular, and cardiovascular disease, and physical examination variables including body mass index (BMI) and systolic and diastolic blood pressure were also recorded. Information about biochemical studies including fasting plasma glucose, total cholesterol, LDL cholesterol, HDL cholesterol, and triglycerides, was recorded for most patients. All patients underwent unenhanced CT scan and/or MRI examinations at diagnosis. All specimens were analyzed following standardized protocols.

The term obesity was defined as a BMI30kg/m2. The remaining patients were included in the “non-obese” group characterized by a BMI<30kg/m2 (both overweight and appropriate weight patients were included here). Overweight was defined as a BMI between 25.0 and 30.0kg/m2. Cardiovascular disease, type 2 diabetes, hypertension and dyslipidemia were defined as we described in a previous work.7

The diagnosis of overt Cushing's syndrome, pheochromocytoma, and primary aldosteronism was based on the latest European guidelines. As we have previously reported,7 autonomous cortisol secretion (ACS) was defined as an adrenal tumor with cortisol post-dexamethasone suppression test (DST)>1.8μg/dl in the absence of specific clinical signs of hypercortisolism.8

Surgical technique and outcomes

Most patients included in the study underwent laparoscopic adrenalectomy as the technique of choice (n=117). There were 29 patients operated on by an open approach. The choice of approach was based on the patient's tumor size and risk of malignancy, with the open approach being more common in patients with large tumors or higher risk of malignancy (adrenal carcinoma). Laparoscopic surgery was performed transperitoneally with the patients placed in a lateral decubitus position. Open surgery was performed through a transabdominal approach using a transverse incision just below the costal margin. All surgeries were conducted under general anesthesia. Only two patients required conversion to laparoscopic approach. All surgeries were conducted under general anesthesia.

As we have previously described,9 the intraoperative complications recorded include hypertensive crisis, intraoperative bleeding, an episode of maintained hypotension, arrhythmias, hemodynamic instability, and conversion to open surgery. Postoperative complications also included hypertensive crisis, a hypotensive episode, hypoglycemia, acute renal failure, paralytic ileus, need for transfusion, postoperative fever, and surgical wound infection. They were also classified based on their severity, following the classical Clavien–Dindo scale.10

Statistical analysis

The statistical analysis was performed using STATA.15. The assumption of normality was checked using the Shapiro–Wilk test. Categorical variables are expressed as percentages and absolute values and quantitative variables as mean±standard deviation or median and ranges depending on whether the variable had a normal distribution. When data are missing for a variable, the number of patients analyzed is indicated. A logistic regression model was used for the estimation of the odds ratios (OR) and 95% confidence intervals. The Chi2 test was performed for the comparison of categorical variables between independent groups and the t-test for comparison between means. In all cases, a two-tailed P value<0.05 or a 95% confidence interval of the OR not including the number 1, were considered statistically significant.

ResultsStudy population

A total of 146 patients were included in the study. The median age was 57.5 years (range 26.9–78.7) and 58.2% were women. There were 14 patients with obesity (9.6%) and 80 patients with overweight (54.8%). In the group of patients with obesity, 10 had grade I obesity and 4 grade II. The main indications of surgery were overt Cushing's syndrome in 18, pheochromocytoma in 36, primary aldosteronism in 30, ACS in 9, and tumor size greater than 40mm and/or atypical features in the remainder. The 6 patients with bilateral tumors had ACS or overt Cushing's syndrome. The baseline characteristics of the patients are described in Table 1.

Table 1.

Baseline characteristics of the cohort study (n=146).

Variable  % (n
Age  56.2±12.51 
Women  58.2% (85) 
Type 2 diabetes  26.7% (39) 
Obesity  9.6% (14) 
Overweight or obesity  64.4% (94) 
Hypertension  63.7% (93) 
Cardiovascular disease  4.1% (6) 
Smoker (n=97)  26.8% (26) 
ASA>2 (n=138)  16.6% (27) 
Functionality  63.7% (93) 
Body mass index, kg/m2  26.3±3.06 
Systolic blood pressure  137.1±15.60 
Diastolic blood pressure  80.0±10.62 
Tumor size  46.5±30.90 
Tumor size40mm  58.2% (85) 
Bilaterality  4.1% (6) 
Calcifications in CT (n=129)  14.7% (19) 
Necrosis in CT (n=129)  7.8% (10) 
Low lipid content (n=128)  92.2% (118) 
Hounsfield units (n=98)  45.2±40.99 
Hounsfield units>10 (n=87)  77.5% (76) 

ASA: American Society of Anesthesiologists classification.

Differences in presurgical and tumor characteristics of patients with and without obesity/overweight

No significant differences in presurgical characteristics were found between patients with and without obesity/overweight, except for a higher proportion of adrenal tumors with high lipid content in obese/overweight patients than in those with normal weight (Table 2). However, when we compared obese and non-obese (including overweight) patients, obese patients had higher diastolic blood pressure (87.6±12.22 vs.79.3±10.23mmHg, P=0.010) and a higher prevalence of dyslipidemia (57.1% vs. 25.8%, P=0.014) and bilateral tumors (14.3% vs. 3.1%, P=0.044) than non-obese patients.

Table 2.

Differences in presurgical, surgical and postsurgical variables between patients with and without obesity/overweight.

Variable  Obese/overweight (N=94)  Normal weight (N=52)  P value 
Presurgical variables
Age  56.5±11.40  55.5±14.40  0.627 
Women  54.3% (43)  34.6% (n=18)  0.192 
Type 2 diabetes  28.7% (27)  23.1% (n=12)  0.460 
Hypertension  68.1% (64)  55.8% (n=29)  0.138 
Cardiovascular disease  3.2% (3)  5.8% (3)  0.452 
Dyslipidemia  33.0% (31)  21.2% (11)  0.131 
Smoker  27.8% (20)  24.0% (6)  0.713 
Pheochromocytoma  26.6% (25)  21.1% (11)  0.465 
Cushing's syndrome  14.9% (14)  7.7% (4)  0.205 
Primary aldosteronism  19.2% (18)  23.1% (12)  0.574 
Autonomous cortisol secretion  5.3% (5)  7.7% (4)  0.568 
ASA>24.4% (21)  11.5% (6)  0.065 
BMI, kg/m2  27.8±2.70  23.6±1.36  <0.001 
Systolic blood pressure  135.6±13.20  139.8±19.05  0.123 
Diastolic blood pressure  80.2±10.87  79.6±10.25  0.749 
Fasting glucose, mg/dl  107.3±46.31  113.9±31.62  0.474 
GFR, ml/min/1.73m2  82.4±12.06  81.6±14.21  0.766 
Tumor size  44.4±27.66  50.1±36.04  0.286 
Tumor size40mm  56.4% (53)  61.5% (32)  0.545 
Bilaterality  6.4% (6)  0%  0.063 
Calcifications in CT (n=129)  10.0% (8)  22.5% (11)  0.053 
Necrosis in CT (n=129)  6.3% (5)  10.2% (5)  0.415 
High lipid content (n=128)  12.5% (10)  0%  0.011 
Hounsfield units (n=98)  49.0±42.83  39.5±37.83  0.263 
Hounsfield units>10 (n=87)  78.0% (46)  76.9% (30)  0.904 
Open adrenalectomy  18.1% (17)  23.1% (12)  0.469 
Surgical and postsurgical variables
Operative time, minutes  124.2±53.21  122.6±50.70  0.878 
Intraoperative complications  6.4% (6)  7.7% (4)  0.764 
Postsurgical complications  9.5% (8)  3.9% (2)  0.228 
Hospital stay, days  3.7±2.20  3.6±2.22  0.793 

ASA: American Society of Anesthesiologists classification; BMI: body mass index; GFR: glomerular filtration rate.

Differences in surgical outcomes of patients with and without obesity/overweight

A total of 10 patients with intraoperative complications were recorded: six patients had intraoperative bleeding, one had a hypertensive crisis together with intraoperative bleeding, one had hemodynamic instability, another patient had hemodynamic instability, asystole and intraoperative death, and the remaining patient was recorded as other complications. Postsurgical complications occurred in 10 patients and 5 were classified as Clavien–Dindo>2 (Fig. 1). The median length of hospital stay across the whole cohort was 3 days (range 2–15 days).

Figure 1.

Rate of intraoperative and postsurgical complications in the global cohort (n=146).

(0.2MB).

The rates of intraoperative and postsurgical complications were similar between obese/overweight patients and patients with normal weight. Nor was a difference found in hospital stay or duration of surgery. However, when we compared obese and non-obese patients, we observed a significantly higher proportion of postsurgical complications in the first group (27.3% vs. 5.7%, P=0.009) than in the second. Moreover, obese patients had a longer hospital stay (5.4±1.39 vs. 3.5±1.78, P=0.007) than non-obese patients (Fig. 2). No correlation was found between BMI and operative time (r=0.044, P=0.639) or hospital stay (r=0.129, P=0.150). In the multivariant analysis, obesity, age, ASA>2, and tumor size were independent risk factors for postoperative complications (Table 3).

Figure 2.

Differences in post-adrenalectomy outcomes between obese and non-obese patients.

(0.26MB).
Table 3.

Risk factors for postsurgical complications.

Variable  Univariate analysis, OR [95% CI], p value  Multivariate analysis, OR [95% CI], p value 
Age  1.12* [1.03–1.22], 0.001  1.14* [1.03–1.26], 0.012 
Women  2.25 [0.60–8.38], 0.221   
Type 2 diabetes  1.94 [0.51–7.31], 0.340   
Obesity  6.27 [1.36–28.96], 0.033  23.34 [2.23–244.24], 0.009 
Overweight and obesity  2.58 [0.53–12.65], 0.208   
Hypertension  2.10 [0.43–10.31], 0.333   
Cardiovascular disease  3.36 [0.34–33.31], 0.353   
ASA>2 (n=138)  7.88 [2.04–30.45], 0.003  8.42 [1.55–45.79], 0.014 
Functionality  0.49 [0.13–1.78], 0.281   
BMI, kg/m2  1.25* [1.03–1.51], 0.031   
Tumor size  1.03* [1.00–1.04], 0.031  1.03* [1.00–1.06], 0.042 
Tumor size40mm  2.76 [0.56–13.52], 0.176   

ASA: American Society of Anesthesiologists classification; BMI: body mass index.

*

Per each increase in unit.

Discussion

Nowadays, obesity/overweight has become an increasingly common feature in patients undergoing surgery, with rates ranging between 39% and 72% of patients undergoing adrenalectomy surgery according to some series.11 In our series, almost 10% of the patients are obese patients and up to 65% are obese or overweight; these rates are similar to other series described in the literature,12 or even have a lower percentage of obesity than other series.11 Moreover, in contrast to other studies, we have also analyzed the influence of overweight compared to obese patients.

In our cohort, obese/overweight patients had higher rates of high blood pressure (68.1%), dyslipidemia (33%) and type 2 diabetes mellitus (28.7%). These data are in agreement with other studies, where patients with obesity have higher rates of cardiovascular risk factors and metabolic syndrome.13 Furthermore, in our series, overweight patients have a higher prevalence of lipid-rich tumors, possibly explained by the fact that patients with metabolic syndrome have a higher tendency to have benign tumors related to Cushing's syndrome or ACS than patients with normal or low weight.14 In contrast, patients with adrenocortical carcinoma, or pheochromocytoma usually have a normal or low BMI. In line with this statement, in our recent study comparing 76 pheochromocytomas and 56 patients with adrenal cortical adenomas with ACS and non-functioning adrenal adenomas, we found that BMI was significantly lower in the first group (24.4±5.7 vs. 26.9±4.3kg/m2, P=0.006).15 Lower BMI is also expected in patients with malignant disease such as adrenocortical carcinoma, in relation to the catabolic effect of the tumor itself.

In addition, we observed that all 6 patients with bilateral tumors were overweight/obese. This finding could be explained by the theory that insulin is able to promote adrenal growth as recognized by Reincke et al.16 who also refer to a proliferative effect of insulin on an adrenal cancer cell line. Moreover, it could be related to the fact that benign adrenocortical adenomas are more commonly bilateral than pheochromocytoma and adrenocortical carcinoma,17 and benign adrenal tumors are more common in obese/overweight than patients with low/normal weight.

Excess body mass is not only associated with a higher prevalence of metabolic syndrome, which can be associated with a higher risk of surgical complications, but it also makes the surgical procedure more difficult in many cases, with increasing demands on the surgeon.6 In our series, we found a complication rate in obese/overweight patients of 15%; this percentage is in keeping with the range of complication rates of laparoscopic adrenalectomy reported in obese patients in the literature (4.6–32%).18 Moreover, in line with other studies, we found higher rates of postsurgical complications (27.3% vs. 5.7%) and a longer hospital stay (5.4±1.39 vs. 3.5±1.78, P=0.007) in obese compared to nonobese patients. However, no differences were found in intraoperative complications and operative time. These results are in agreement with those described in other studies such as the Dancea et al. series19 that concluded that obesity was associated with increased complications. The conversion rate to open surgery in laparoscopic adrenalectomy may vary from 1 to 22%.20 One of the causes of conversion is obesity, but it may also be caused by uncontrollable bleeding, large masses or invasion of adjacent structures. In our study, there are only 2 cases (1.4%) of conversion to open surgery, but they are not related to obesity in either case.

In contrast with our results, other studies such as the Pedziwiatr et al. study11 found no significant differences in short-term outcomes (operative time, blood loss, conversion and complication rates, hospital stay, or readmissions) between normal weight, overweight, obese, and morbidly obese patients. These differences may be related to the different study design, the included study population (patients with or without malignant adrenal tumors), and the definitions employed for obesity and surgical complications, that are not always the same.

Other studies have reported that surgical complications were higher in patients with ASA grade>2, previous abdominal surgery, obesity, diabetes, and larger tumor size.21 In this vein, in our series, the multivariate analysis showed that obesity, age, ASA>2, and tumor size were independent risk factors for postoperative complications; with obesity being the most important factor, with an OR of 23.3 in comparison with non-obese patients. Despite a higher rate of surgical complications in obese patients, laparoscopic adrenalectomy should also be considered the technique of choice in these patients.11 In addition, other authors state that age ≥70 years, ASA3, BMI35kg/m2, tumor6cm, and previous upper abdominal surgery should not be considered contraindications for laparoscopic adrenalectomy,20 since they found that the only independent predictive factors in the multivariable logistic regression analysis for overall complications were conversion to open surgery (OR 6.2) and left-sided laparoscopic adrenalectomy (OR 1.89). In accordance with this study, despite our having found a higher rate of complications in obese compared to non-obese patients, we believe that with adequate experience, laparoscopic adrenalectomy can be a feasible and safe technique in obese patients.

We are aware that our study has several limitations. Firstly, the main limitation is the retrospective nature of study. However, the inclusion of the patients was consecutive, reducing the possibility of selection biases. Secondly, the study was carried out in a single center that is considered a reference center for the management of adrenal tumors, with a high volume of adrenalectomies per year, so our results are probably not representative of other centers with a lower number of adrenalectomies and with less complex cases. Moreover, our series included patients with different etiologies of adrenal tumors, and although we did not find differences in the etiology of these tumors depending on weight status, it is possible that some specific types of tumors are more common in patients with overweight/obesity, like Cushing's syndrome and ACS.21 In addition, it would have been interesting to have information about waist circumference to determine the prevalence of visceral obesity, since it is possible that the association of waist circumference with intraoperative and postoperative complications was even higher than those we have obtained, even in overweight patients.22 In the same vein, we are aware that BMI is an inaccurate marker for estimating overall body composition. Information about the proportion of muscle mass and fat mass would allow us to establish the prevalence of sarcopenic obesity, which is related to a higher rate of complications than non-sarcopenic obesity.23

Conclusion

Obesity and overweight are common conditions in patients who undergo adrenalectomy. Adrenalectomy is considered a safe procedure in patients with overweight, but it is associated with a higher risk of postsurgical complications and longer hospital stay in obese patients compared to patients with overweight and normal weight. Thus, obesity is an independent risk factor of postsurgical complications that needs to be considered in surgical decisions of adrenalectomy.

Authors’ contributions

César Mínguez Ojeda and Marta Araujo-Castro wrote the draft of the manuscript, all authors have reviewed and approved the final version of the article.

Ethical approval

All procedures performed in the participants of the study were in accordance with the ethical standards of the institutional research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. The study was evaluated and approved by the Ethics Committee of Hospital Universitario Ramón y Cajal ((approval date: July 2020, Minutes 395).

Data availability statement

The data that support the findings of this study are available on request from the corresponding author. The data are not publicly available due to privacy or ethical restrictions.

Financial support

SENDIMAD [Sociedad de Endocrinología, Nutrición y Diabetes de la Comunidad de Madrid, Endocrinology, Nutrition and Diabetes Society of the Community of Madrid]: BECA SENDIMAD de Ayuda a la Investigación en Endocrinología, Nutrición y Diabetes 2019 [SENDIMAD GRANT in Support of Research in Endocrinology, Nutrition and Diabetes 2019].

IRYCIS [Instituto Ramón y Cajal de Investigación Sanitaria, Ramón y Cajal Health Research Institute]: Convocatoria intramural de ayudas a proyectos de investigación de investigadores noveles, investigadores clínicos asociados y/o grupos emergentes del Hospital Universitario Ramón y Cajal 2019 [Intramural call for grant applications for research projects by new researchers, clinical research associates and/or emerging groups of Hospital Universitario Ramón y Cajal (Ramón y Cajal University Hospital) 2019].

Conflict of interest

The authors have no conflict of interest.

References
[1]
E.S. Ford, W.H. Giles, W.H. Dietz.
Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey.
JAMA, 287 (2002), pp. 356-359
[2]
O.A. Shariq, K.M. Fruth, K.T. Hanson, P.A. Cronin, M.L. Richards, D.R. Farley, et al.
Metabolic syndrome is associated with increased postoperative complications and use of hospital resources in patients undergoing laparoscopic adrenalectomy.
Surgery, 163 (2018), pp. 167-175
[3]
M. Pedziwiatr, M. Wierdak, M. Ostachowski, M. Natkaniec, M. Białas, A. Hubalewska-Dydejczyk, et al.
Single center outcomes of laparoscopic transperitoneal lateral adrenalectomy – lessons learned after 500 cases: a retrospective cohort study.
Int J Surg, 20 (2015), pp. 88-94
[4]
T. Coste, R. Caiazzo, F. Torres, M.C. Vantyghem, B. Carnaille, F. Pattou, et al.
Laparoscopic adrenalectomy by transabdominal lateral approach: 20 years of experience.
Surg Endosc, 31 (2017), pp. 2743-2751
[5]
J.M. Villar, P. Moreno, J. Ortega, E. Bollo, C.P. Ramírez, N. Muñoz, et al.
Results of adrenal surgery. Data of a Spanish National Survey.
Langenbeck's Arch Surg, 395 (2010), pp. 837-843
[6]
J.I. Rodríguez-Hermosa, P. Planellas-Giné, L. Cornejo, J. Gironès, M. Recasens, F.J. Ortega, et al.
Comparison of outcomes between obese and nonobese patients in laparoscopic adrenalectomy: a cohort study.
Dig Surg, 38 (2021), pp. 237-246
[7]
M. Araujo-Castro, C. Mínguez Ojeda, M.N. Sánchez Ramírez, V. Gómez Dos Santos, E. Pascual-Corrrales, M. Fernández-Argüeso.
Adrenalectomy improves blood pressure control in nonfunctioning adrenal incidentalomas and glycemic and lipid control in patients with autonomous cortisol secretion.
[8]
M. Araujo-Castro, M.A. Sampedro Núñez, M. Marazuela.
Autonomous cortisol secretion in adrenal incidentalomas.
[9]
C. Mínguez Ojeda, V. Gómez Dos Santos, J. Álvaro Lorca, I. Ruz-Caracuel, H. Pian, A. Sanjuanbenito Dehesa, et al.
Tumour size in adrenal tumours: its importance in the indication of adrenalectomy and in surgical outcomes – a single-centre experience.
J Endocrinol Invest, 45 (2022), pp. 1999-2006
[10]
D. Dindo, N. Demartines, P.A. Clavien.
Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey.
[11]
M. Pędziwiatr, P. Major, M. Pisarska, M. Natkaniec, M. Godlewska, K. Przęczek, et al.
Laparoscopic transperitoneal adrenalectomy in morbidly obese patients is not associated with worse short-term outcomes.
Int J Urol, 24 (2017), pp. 59-63
[12]
Y. Erbil, U. Barbaros, S. Sari, O. Agcaoglu, A. Salmaslioglu, S. Ozarmagan.
The effect of retroperitoneal fat mass on surgical outcomes in patients performing laparoscopic adrenalectomy: the effect of fat tissue in adrenalectomy.
Surg Innov, 17 (2010), pp. 114-119
[13]
M. Kostapanos, M. Florentin, M. Elisaf, D. Mikhailidis.
Hemostatic factors and the metabolic syndrome.
Curr Vasc Pharmacol, 11 (2013), pp. 880-905
[14]
M. Terzolo, A. Pia, A. Alì, G. Osella, G. Reimondo, S. Bovio, et al.
Adrenal incidentaloma: a new cause of the metabolic syndrome?.
J Clin Endocrinol Metab, 87 (2002), pp. 998-1003
[15]
M. Araujo-Castro, I. García Sanz, C. Mínguez Ojeda, M. Calatayud, F. Hanzu, M. Mora, et al.
Differences in intraoperative and surgical outcomes between normotensive pheochromocytomas and sympathetic paragangliomas (PPGLs) and hypertensive PPGLs: results from the PHEO-RISK STUDY.
J Endocrinol Invest, 46 (2023), pp. 805-814
[16]
M. Reincke, M. Faßnacht, S. Väth, P. Mora, B. Allolio.
Adrenal incidentalomas: a manifestation of the metabolic syndrome?.
Endocr Res, 22 (1996), pp. 757-761
[17]
M. Araujo-Castro, R. García Centeno, C. Robles Lázaro, P. Parra Ramírez, P. Gracia Gimeno, P.M. Rojas-Marcos, et al.
Predictive model of pheochromocytoma based on the imaging features of the adrenal tumours.
[18]
D. Paun, R. Petris, R. Ganescu, S. Paun, M. Vartic, M. Beuran.
Outcome of laparoscopic adrenalectomy in obese patients.
Maedica (Buchar), 10 (2015), pp. 231-236
[19]
H.C. Dancea, V. Obradovic, J. Sartorius, N. Woll, J.A. Blansfield.
Increased complication rate in obese patients undergoing laparoscopic adrenalectomy.
J Soc Laparoendosc Surg, 16 (2012), pp. 45-49
[20]
S. Gaujoux, S. Bonnet, M. Leconte, S. Zohar, J. Bertherat, X. Bertagna, et al.
Risk factors for conversion and complications after unilateral laparoscopic adrenalectomy.
Br J Surg, 98 (2011), pp. 1392-1399
[21]
J. Wagner, D.C. Aron.
Incidentalomas – a “disease” of modern imaging technology.
Best Pract Res Clin Endocrinol Metab, 26 (2012), pp. 3-8
[22]
L. Han, C. Deng, R. Zhao, Q. Wan, X. Zhang, X. Wang, et al.
Excess visceral fat area as an independent risk factor for early postoperative complications in patients with obesity undergoing bariatric surgery.
Front Endocrinol (Lausanne), (2023), pp. 14
[23]
A. Jones, H.J. Silver.
Myosteatotic and sarcopenic obesity impact postoperative outcomes more robustly than visceral obesity in general surgery patients, with differences by sex.
Clin Nutr, 42 (2023), pp. 625-635
Copyright © 2023. SEEN y SED
Download PDF
Article options
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos